Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04141761

Probiotics in Newly Diagnosed T1D

The investigators aim to further the understanding of environmental factors that underlie the development of Type 1 diabetes (T1D) and the post-onset disease trajectory. Dysbiosis, defined as alterations in intestinal microbiota composition and function, has been hypothesized to increase the risk of developing T1D in those with genetic susceptibility. Dysbiosis may result from modern dietary habits, such as broad consumption of the highly processed Western Diet, or by widespread use of antibiotics. Here, the investigators propose to examine the impact of dysbiosis on the endogenous innate inflammatory state that potentiates T1D progression. The investigators hypothesize that probiotic-induced alterations in the intestinal microbiota may favorably alter the post-onset disease state.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Type 1 Diabetes Autoimmune Diseases Diabetes Mellitus Diabetes Mellitus, Type 1 Endocrine System Diseases Glucose Metabolism Disorders Immune System Diseases Metabolic Diseases Nutritional and Metabolic Diseases Type 1 Diabetes Mellitus Type1diabetes

Age range

5 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must meet all of the following criteria:
  • Males and females 5-17 years of age with a clinical diagnosis of T1D within the past 90 days
  • Positive for ≥ 1 diabetes-related autoantibodies (IAA, GAD, IA-2, or ZnT8)
  • Stimulated C-peptide area under the curve (AUC) of ≥ 0.2 nmol/L during a mixed meal tolerance test
  • Treatment naïve of any immunomodulatory agent

Exclusion criteria

  • Patients must NOT meet any of the following criteria:
  • Probiotic use within 1 month of screening visit
  • Presence of severe, active disease that requires the use of chronic medication, with the exception of well-controlled autoimmune thyroiditis/hypothyroidism
  • Diabetes other than T1D
  • Female participants of child-bearing age with reproductive potential must not be knowingly pregnant
  • Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results

Treatment and study plan

Visbiome

Dietary Supplement

This group will receive Visbiome probiotic in powder form.

Placebo

Other

This group will receive a placebo in powder form.

Primary outcomes

  1. Effect of Multistrain Probiotic on Immune System Inflammation as measured by plasma transcription analysis

    Time frame: 3 years (duration of study)

    Investigators will examine the effect of multistrain probiotic supplementation on the endogenous innate inflammatory state in youth newly diagnosed with T1D, as measured by plasma-induced transcription analysis. The investigators hypothesize that the participants receiving the probiotic will have less inflammation (as measured by transcriptional analysis) than the participants in the placebo group.

Secondary outcomes

  1. C-peptide decline

    Time frame: 3 years (duration of study)

    Investigators will examine the effect of multistrain probiotic supplementation on the post-onset rate of C-peptide decline (a measure of beta cell health)

  2. Effect of Multistrain Probiotic on broader Immune System Effects as measured by plasma-induced transcriptional analyses

    Time frame: 3 years (duration of study)

    Investigators will examine the effect of multistrain probiotic supplementation on changes to the plasma-induced transcriptional assay to assess for probiotic-specific immune effects. Plasma-induced transcriptional analyses will be compared before and after treatment with probiotic/placebo. The investigators hypothesize that the participants receiving the probiotic will see reduced inflammation (as measured by transcriptional analysis) while those that received the placebo will see no change or increased inflammation.

  3. Cytokine Levels (a measure of inflammation) as measured by plasma analysis

    Time frame: 3 years (duration of study)

    Cytokine levels before and after treatment will be measured by plasma analysis. It is hypothesized that the levels of cytokines in the blood will be lower after treatment for the participants receiving the probiotic but not for those receiving the placebo.

  4. Changes to intestinal bacteria as measured by stool analysis

    Time frame: 3 years (duration of study)

    Investigators will examine the effect of multistrain probiotic supplementation the composition of the intestinal microbiota

  5. System-wide Effects as measured by systemic microbial antigen (a marker of intestinal permeability) as measured by plasma analysis

    Time frame: 3 years (duration of study)

    Gut leakiness will be measured by examining the levels of microbial antigens in the plasma before and after treatment and correlating these antigen levels with the changes in the composition of the gut bacteria. It is hypothesized that changes in antigen levels and gut bacteria will only be seen in the participants receiving the probiotic. It is further hypothesized that those with the greatest reduction in antigens will have the most significant changes in gut bacteria composition.

Sponsors and collaborators

Lead sponsor

Medical College of Wisconsin

Other

Registry information

Official study title

Probiotic-induced Normalization of Innate Inflammation in Youth Newly Diagnosed With Type 1 Diabetes

Important dates

Study start
2019
Primary completion
2023
Study completion
2027
First posted
Oct 28, 2019
Registry last updated
Oct 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.